^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 negative + AR positive + ER positive

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; ESR1, Era, ESR, NR3A1, ER, ER beta; AR, AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1, Androgen receptor
    Entrez ID:
    2064; 2099; 367
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    3d
    A Multicenter Randomized Controlled Clinical Trial of Neoadjuvant Endocrine Therapy versus Chemotherapy in Patients with HR+/HER2- Early-Stage Breast Cancer (ChiCTR2500111780)
    P4, N=148, Not yet recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    paclitaxel • cyclophosphamide • Kisqali (ribociclib) • letrozole • epirubicin • goserelin acetate
    6d
    Late Cervical Recurrence of Invasive Lobular Carcinoma Ten Years After Primary Breast Cancer: A Case Report and Review of the Literature. (PubMed, Healthcare (Basel))
    The patient began systemic therapy with ribociclib plus letrozole, achieving radiologic improvement of the cervical lesion and abdominal disease. This case highlights the ability of ILC to recur after long latency and to metastasize to unusual gynecologic sites such as the cervix. We also review the literature on cervical recurrence from lobular carcinoma to emphasize the importance of gynecologic surveillance in breast cancer survivors and to identify areas that require further investigation.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • CDH1 (Cadherin 1) • CDX2 (Caudal Type Homeobox 2) • GATA3 (GATA binding protein 3)
    |
    ER positive • HER-2 negative • BRCA mutation • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Kisqali (ribociclib) • letrozole
    8d
    DNACDKHR: CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment (clinicaltrials.gov)
    P2, N=158, Not yet recruiting, Peking University People's Hospital
    New P2 trial • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    12d
    DNADalHR: ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=393, Recruiting, Peking University People's Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    paclitaxel • docetaxel • cyclophosphamide • exemestane • AiRuiKang (dalpiciclib)
    17d
    A Case of Tubular Carcinoma of the Breast (PubMed, Gan To Kagaku Ryoho)
    Tubular carcinoma is pathologically characterized by a high amount of fibrous stroma surrounding the lumen, and ultrasound findings often show a hypoechoic mass with unclear boundaries and attenuation of posterior echoes. In this case, ultrasound examination was also useful in estimating the histological type.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    21d
    Temporal Trends in Clinicopathological Features and Outcomes of De Novo Metastatic Luminal A Breast Cancer: A Retrospective Multicenter Analysis (2017-2025). (PubMed, Cancer Invest)
    These findings suggest a temporal shift toward a more aggressive biological phenotype, underscoring the clinical relevance of monitoring proliferation indices even within the Luminal A subtype. While causality cannot be inferred, identification of a clinically actionable Ki-67 threshold may aid risk stratification and supports future research integrating molecular profiling to clarify mechanisms underlying temporal biological change.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + AR positive + ER positive
    29d
    CLINICAL RELEVANCE OF HORMONAL RECEPTOR EXPRESSION IN BREAST CANCER: AN IMMUNOHISTOCHEMICAL STUDY FROM TRIPOLI, LIBYA. (PubMed, Exp Oncol)
    The findings highlight the predominance of hormone receptor-positive and HER2-negative tumors in this Libyan cohort.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    1m
    AutoEpiCollect 2.0: A Web-Based Machine Learning Tool for Personalized Peptide Cancer Vaccine Design. (PubMed, Molecules)
    Furthermore, by applying RNAseq in a standardized workflow, the approach enables both patient-specific and population-level vaccine design, based on statistically frequent gene variants observed across tumor datasets. AutoEpiCollect 2.0 is freely available as a website based tool for user to design vaccine.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA2 (Breast cancer 2, early onset) • AHNAK2 (AHNAK Nucleoprotein 2) • MUC5AC (Mucin 5AC)
    |
    ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    1m
    LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Centre, Singapore | Trial completion date: Sep 2027 --> Dec 2027 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • letrozole
    1m
    Assessing barriers to genomic testing in breast cancer among diverse patients: a qualitative community-engaged research study. (PubMed, Breast Cancer Res Treat)
    Equitable delivery of genomic testing in breast cancer requires multilevel interventions targeting structural barriers, administrative complexity, and culturally tailored education. Addressing these barriers is likely to reduce disparities and further improve health equity in cancer care.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    2ms
    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
    P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial primary completion date: Dec 2025 --> May 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive
    |
    methotrexate IV
    2ms
    Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer (clinicaltrials.gov)
    P4, N=75, Recruiting, Hebei Medical University Fourth Hospital | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Oct 2024 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Avastin (bevacizumab)